TY - JOUR
T1 - Utility of serum HER2 extracellular domain assessment in clinical decision making
T2 - Pooled analysis of four trials of trastuzumab in metastatic breast cancer
AU - Leyland-Jones, Brian
AU - Lennon, Sian
AU - Barton, Claire
AU - Banken, Ludger
AU - Gianni, Luca
AU - Marty, Michel
AU - Baselga, José
PY - 2009/4/1
Y1 - 2009/4/1
N2 - Purpose Trastuzumab is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2(HER2). Trastuzumab alone or in combination with chemotherapy has been shown to be effective in patients with HER2-positive early and metastatic breast cancer. The extracellular domain(ECD) of the HER2 protein may be shed into the serum and is detectable using an enzyme-linked immunosorbent assay. Correlations have been reported between raised baseline ECD levels and response to trastuzumab, suggesting that serum ECD levels may be useful in making treatment decisions in patients with HER2-positive breast cancer. We investigated this relationship, and also the effect of trastuzumab and chemotherapy on ECD levels, in patients with advanced breast cancer. Methods This study analyzed sequential ECD determinations on 322 patients treated with six different treatment regimens in four clinical trials. Results Baseline values were available in 296 patients, and of these, 205(69%) had raised levels(> 15 ng/mL). No clear relationship was found between baseline ECD levels and tumor response. After initiating combination therapy, ECD levels declined irrespective of treatment received and tumor response. For trastuzumab monotherapy, some trend between changes in ECD levels in early cycles and best response was discernable, but the overlap was too broad to be clinically useful. Disease progression was not reliably predicted by rising ECD levels in the majority of patients. Conclusion Based on our data, we cannot recommend using serum HER2 ECD levels to make trastuzumab or other treatment decisions for individual patients with advanced/metastatic breast cancer.
AB - Purpose Trastuzumab is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2(HER2). Trastuzumab alone or in combination with chemotherapy has been shown to be effective in patients with HER2-positive early and metastatic breast cancer. The extracellular domain(ECD) of the HER2 protein may be shed into the serum and is detectable using an enzyme-linked immunosorbent assay. Correlations have been reported between raised baseline ECD levels and response to trastuzumab, suggesting that serum ECD levels may be useful in making treatment decisions in patients with HER2-positive breast cancer. We investigated this relationship, and also the effect of trastuzumab and chemotherapy on ECD levels, in patients with advanced breast cancer. Methods This study analyzed sequential ECD determinations on 322 patients treated with six different treatment regimens in four clinical trials. Results Baseline values were available in 296 patients, and of these, 205(69%) had raised levels(> 15 ng/mL). No clear relationship was found between baseline ECD levels and tumor response. After initiating combination therapy, ECD levels declined irrespective of treatment received and tumor response. For trastuzumab monotherapy, some trend between changes in ECD levels in early cycles and best response was discernable, but the overlap was too broad to be clinically useful. Disease progression was not reliably predicted by rising ECD levels in the majority of patients. Conclusion Based on our data, we cannot recommend using serum HER2 ECD levels to make trastuzumab or other treatment decisions for individual patients with advanced/metastatic breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=63749132329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63749132329&partnerID=8YFLogxK
U2 - 10.1200/JCO.2008.16.8351
DO - 10.1200/JCO.2008.16.8351
M3 - Article
C2 - 19255335
AN - SCOPUS:63749132329
VL - 27
SP - 1685
EP - 1693
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 10
ER -